Skip to main content
SpringerLink
Log in

Prostacyclins

  • Chapter
  • First Online:
Pharmacotherapy of Pulmonary Hypertension

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 218))

Abstract

Prostacyclins have a favourable pharmacological profile for treatment of pulmonary hypertension as they possess vasodilative, antiproliferative, antiaggregatory, and anti-inflammatory properties that may compensate the main pathologic changes in the small pulmonary arteries. In severe pulmonary hypertension these vessels show a deficit in the endogenous prostacyclin secretion. The therapeutic potential of prostacyclin for pulmonary hypertension has been known since 30 years, and since nearly 20 years prostacyclin has been approved for idiopathic PAH. There are intravenous, subcutaneous, and inhaled approaches of different substances who share many but not all pharmacologic properties. However, none of these approaches are easy and free of adverse effects. Long-term experience and careful decision-making are instrumental to achieve favourable clinical long-term results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, Metters KM (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483:285–293

    Article  PubMed  CAS  Google Scholar 

  • Aguilar RV, Farber HW (2000) Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 162:1846–1850

    Article  PubMed  CAS  Google Scholar 

  • Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425–434

    Article  PubMed  CAS  Google Scholar 

  • Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131:1917–1928

    Article  PubMed  Google Scholar 

  • Barger PM (2002) Has angiogenesis been invited to the PPARty? J Mol Cell Cardiol 34:713–716

    Article  PubMed  CAS  Google Scholar 

  • Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296–302

    Article  PubMed  CAS  Google Scholar 

  • Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–2125

    Article  PubMed  CAS  Google Scholar 

  • Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin LJ (2006) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28:1195–1203

    Article  PubMed  CAS  Google Scholar 

  • Bhattacharya M, Peri KG, Almazan G, Ribeiro-da-Silva A, Shichi H, Durocher Y, Abramovitz M, Hou X, Varma DR, Chemtob S (1998) Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 95:15792–15797

    Article  PubMed  CAS  Google Scholar 

  • Bhattacharya M, Peri K, Ribeiro-da-Silva A, Almazan G, Shichi H, Hou X, Varma DR, Chemtob S (1999) Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem 274:15719–15724

    Article  PubMed  CAS  Google Scholar 

  • Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 134:44–54

    Article  PubMed  CAS  Google Scholar 

  • Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ (2006) Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 48:1433–1437

    Article  PubMed  CAS  Google Scholar 

  • Chow KB, Jones RL, Wise H (2003) Protein kinase A-dependent coupling of mouse prostacyclin receptors to Gi is cell-type dependent. Eur J Pharmacol 474:7–13

    Article  PubMed  CAS  Google Scholar 

  • Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A (2002) Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 26:194–201

    Article  PubMed  CAS  Google Scholar 

  • Cornwell WK, McLaughlin VV, Krishnan SM, Rubenfire M (2011) Does the outcome justify an oral-first treatment strategy for management of pulmonary arterial hypertension? Chest 140:697–705

    Article  PubMed  Google Scholar 

  • Ewert R, Opitz CF, Wensel R, Winkler J, Halank M, Felix SB (2007) Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol 96:211–217

    Article  PubMed  CAS  Google Scholar 

  • Fontana M, Olschewski H, Olschewski A, Schluter KD (2007) Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. Br J Pharmacol 151:779–786

    Article  PubMed  CAS  Google Scholar 

  • Forman BM, Umesono K, Chen J, Evans RM (1995) Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81:541–550

    Article  PubMed  CAS  Google Scholar 

  • Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502

    Article  PubMed  CAS  Google Scholar 

  • Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Sechtem U, Al AN, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Domenech MT, Vonk-Noordegraaf A, Zamorano JL (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–2537

    Article  PubMed  Google Scholar 

  • Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522

    Article  PubMed  CAS  Google Scholar 

  • Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42:158–164

    Article  PubMed  CAS  Google Scholar 

  • Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F, Lohmeyer J (2004) Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 23:321–326

    Article  PubMed  CAS  Google Scholar 

  • Gomberg-Maitland M, Olschewski H (2008) Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31:891–901

    Article  PubMed  CAS  Google Scholar 

  • Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, Barst RJ (2005a) Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172:1586–1589

    Article  PubMed  Google Scholar 

  • Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S (2005b) Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 96:1334–1336

    Article  PubMed  CAS  Google Scholar 

  • Gryglewski RJ (1980) Prostaglandins, platelets, and atherosclerosis. CRC Crit Rev Biochem 7:291–338

    Article  PubMed  CAS  Google Scholar 

  • Gunther S, Jais X, Maitre S, Berezne A, Dorfmuller P, Seferian A, Savale L, Mercier O, Fadel E, Sitbon O, Mouthon L, Simonneau G, Humbert M, Montani D (2012) Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum 64:2995–3005

    Article  PubMed  CAS  Google Scholar 

  • Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 97:13275–13280

    Article  PubMed  CAS  Google Scholar 

  • Hall H, Cote J, McBean A, Purden M (2012) The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart Lung 41:35–43

    Article  PubMed  Google Scholar 

  • Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T (2001) Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem 276:46260–46267

    Article  PubMed  CAS  Google Scholar 

  • Higenbottam T, Wheeldon D, Wells F, Wallwork J (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1:1046–1047

    Article  PubMed  CAS  Google Scholar 

  • Higenbottam TW, Butt AY, Dinh-Xuan AT, Takao M, Cremona G, Akamine S (1998) Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79:175–179

    PubMed  CAS  Google Scholar 

  • Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E (2003) Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 22:330–334

    Article  PubMed  CAS  Google Scholar 

  • Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R, Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J (2006) Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28:691–694

    Article  PubMed  CAS  Google Scholar 

  • Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, Parent F, Simonneau G (1999) Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 13:1351–1356

    Article  PubMed  CAS  Google Scholar 

  • Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G (2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24:353–359

    Article  PubMed  CAS  Google Scholar 

  • Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, Brady D, Law Y, Parker D, Claussen L, Abman SH (2008) Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51:161–169

    Article  PubMed  CAS  Google Scholar 

  • Keith RL, Geraci MW (2006) Prostacyclin in lung cancer. J Thorac Oncol 1:503–505

    Article  PubMed  Google Scholar 

  • Kemp K, Savale L, O’Callaghan DS, Jais X, Montani D, Humbert M, Simonneau G, Sitbon O (2012) Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 31:150–158

    Article  PubMed  Google Scholar 

  • Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R (2007) How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med 175:846–850

    Article  PubMed  CAS  Google Scholar 

  • Kitterman N, Poms A, Miller DP, Lombardi S, Farber HW, Barst RJ (2012) Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY(R). Mayo Clin Proc 87:825–834

    Article  PubMed  Google Scholar 

  • Krowka MJ, Swanson KL (2006) How should we treat portopulmonary hypertension? Eur Respir J 28:466–467

    Article  PubMed  CAS  Google Scholar 

  • Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, Vachiery JL (2006) Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129:1636–1643

    Article  PubMed  CAS  Google Scholar 

  • le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH (2002) Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 283:L555–L562

    PubMed  Google Scholar 

  • Li Y, Connolly M, Nagaraj C, Tang B, Balint Z, Popper H, Smolle-Juettner FM, Lindenmann J, Kwapiszewska G, Aaronson PI, Wohlkoenig C, Leithner K, Olschewski H, Olschewski A (2012) Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation. Am J Respir Cell Mol Biol 46:372–379

    Article  PubMed  CAS  Google Scholar 

  • McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106:1477–1482

    Article  PubMed  CAS  Google Scholar 

  • McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174:1257–1263

    Article  PubMed  CAS  Google Scholar 

  • McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55:1915–1922

    Article  PubMed  CAS  Google Scholar 

  • Meyer-Kirchrath J, Debey S, Glandorff C, Kirchrath L, Schror K (2004) Gene expression profile of the G(s)-coupled prostacyclin receptor in human vascular smooth muscle cells. Biochem Pharmacol 67:757–765

    Article  PubMed  CAS  Google Scholar 

  • Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663–665

    Article  PubMed  CAS  Google Scholar 

  • Montani D, Price LC, Dorfmuller P, Achouh L, Jais X, Yaici A, Sitbon O, Musset D, Simonneau G, Humbert M (2009) Pulmonary veno-occlusive disease. Eur Respir J 33:189–200

    Article  PubMed  CAS  Google Scholar 

  • Morrison K, Studer R, Ernst R, Haag F, Kauser K, Clozel M (2012) Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery. J Pharmacol Exp Ther 343:547–555

    Article  PubMed  CAS  Google Scholar 

  • Nagaraj C, Tang B, Balint Z, Wygrecka M, Hrzenjak A, Kwapiszewska G, Stacher E, Lindenmann J, Weir EK, Olschewski H, Olschewski A (2012) Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 41(1):85–95

    Article  PubMed  Google Scholar 

  • Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Herve P, Barst RJ, Simonneau G (2003) Prognostic factors for survival in HIV-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 167:1433–1439

    Article  PubMed  Google Scholar 

  • O’Grady J, Warrington S, Moti MJ, Bunting S, Flower R, Fowle AS, Higgs EA, Moncada S (1980) Effects of intravenous infusion of prostacyclin (PGI2) in man. Prostaglandins 19:319–332

    PubMed  Google Scholar 

  • Olschewski H, Olschewski A (2011) Pulmonale hypertonie, 2nd edn. Uni-Med Science, Bremen

    Google Scholar 

  • Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124:820–824

    Article  PubMed  CAS  Google Scholar 

  • Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W (1999) Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160:600–607

    Article  PubMed  CAS  Google Scholar 

  • Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM, Behr J, Kleber FX, Seeger W (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132:435–443

    Article  PubMed  CAS  Google Scholar 

  • Olschewski H, Rose F, Grunig E, Ghofrani HA, Walmrath D, Schulz R, Schermuly R, Grimminger F, Seeger W (2001a) Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med 138:367–377

    Article  PubMed  CAS  Google Scholar 

  • Olschewski H, Olschewski A, Rose F, Schermuly R, Schutte H, Weissmann N, Seeger W, Grimminger F (2001b) Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 138:287–297

    Article  PubMed  CAS  Google Scholar 

  • Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329

    Article  PubMed  CAS  Google Scholar 

  • Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, Schmehl T (2003) Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 124:1294–1304

    Article  PubMed  CAS  Google Scholar 

  • Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM, Wilhelm J, Morty RE, Brau ME, Weir EK, Kwapiszewska G, Klepetko W, Seeger W, Olschewski H (2006) Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 98:1072–1080

    Article  PubMed  CAS  Google Scholar 

  • Olschewski H, Hoeper MM, Behr J, Ewert R, Meyer A, Borst MM, Winkler J, Pfeifer M, Wilkens H, Ghofrani HA, Nikkho S, Seeger W (2010) Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 104:731–740

    Article  PubMed  Google Scholar 

  • Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT (2012) Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 110(10):1546–1550

    Article  Google Scholar 

  • Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marce M, Losordo DW, Smith RC, Pola P (2004) Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 36:363–370

    Article  PubMed  CAS  Google Scholar 

  • Rabiller A, Jais X, Hamid A, Resten A, Parent F, Haque R, Capron F, Sitbon O, Simonneau G, Humbert M (2006) Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 27:108–113

    Article  PubMed  CAS  Google Scholar 

  • Reginato MJ, Krakow SL, Bailey ST, Lazar MA (1998) Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem 273:1855–1858

    Article  PubMed  CAS  Google Scholar 

  • Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, Grimminger F, Seeger W, Ghofrani HA (2006) Sildenafil treatment for portopulmonary hypertension. Eur Respir J 28:563–567

    Article  PubMed  CAS  Google Scholar 

  • Robbins IM, Christman BW, Newman JH, Matlock R, Loyd JE (1998) A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 114:1269–1275

    Article  PubMed  CAS  Google Scholar 

  • Rose F, Hattar K, Gakisch S, Grimminger F, Olschewski H, Seeger W, Tschuschner A, Schermuly RT, Weissmann N, Hanze J, Sibelius U, Ghofrani HA (2003) Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost. Thromb Haemost 90:1141–1149

    PubMed  CAS  Google Scholar 

  • Rosenzweig EB, Kerstein D, Barst RJ (1999) Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99:1858–1865

    Article  PubMed  CAS  Google Scholar 

  • Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE (1982) Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 66:334–338

    Article  PubMed  CAS  Google Scholar 

  • Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800–804

    Article  PubMed  Google Scholar 

  • Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149:521–530

    Article  PubMed  Google Scholar 

  • Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie N, Degano B, Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM (2012) Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 40:874–880

    Article  PubMed  CAS  Google Scholar 

  • Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40:780–788

    Article  PubMed  CAS  Google Scholar 

  • Sitbon O, Manes A, Jais X, Pallazini M, Humbert M, Presotto L, Paillette L, Zaccardelli D, Davis G, Jeffs R, Simonneau G, Galie N (2007) Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 49:1–5

    Article  PubMed  CAS  Google Scholar 

  • Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM (2012) Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 186:261–272

    Article  PubMed  Google Scholar 

  • Sussmann M, Sarbia M, Meyer-Kirchrath J, Nusing RM, Schror K, Fischer JW (2004) Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins. Circ Res 94:592–600

    Article  PubMed  CAS  Google Scholar 

  • Tang B, Li Y, Nagaraj C, Morty RE, Gabor S, Stacher E, Voswinckel R, Weissmann N, Leithner K, Olschewski H, Olschewski A (2009) Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 41:476–483

    Article  PubMed  CAS  Google Scholar 

  • Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc MG, Waltenberger J, Voelkel NF, Tuder RM (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15:427–438

    Article  PubMed  CAS  Google Scholar 

  • Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, Gall H, Gessler T, Schmehl T, Ghofrani HA, Schermuly RT, Grimminger F, Rubin LJ, Seeger W, Olschewski H (2006) Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 48:1672–1681

    Article  PubMed  CAS  Google Scholar 

  • Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, Seeger W, Ghofrani HA (2008) Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 25:824–832

    Article  Google Scholar 

  • Voswinckel R, Reichenberger F, Gall H, Schmehl T, Gessler T, Schermuly RT, Grimminger F, Rubin LJ, Seeger W, Ghofrani HA, Olschewski H (2009) Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther 22:50–56

    Article  PubMed  CAS  Google Scholar 

  • Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W (1993) Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 342:961–962

    Article  PubMed  CAS  Google Scholar 

  • Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W (1996) Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 153:991–996

    Article  PubMed  CAS  Google Scholar 

  • Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Elliott CG, Fishman AP, Goldring RM, Groves BM (1989) The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 140:1623–1630

    Article  PubMed  CAS  Google Scholar 

  • Wise H (2003) Multiple signalling options for prostacyclin. Acta Pharmacol Sin 24:625–630

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Horst Olschewski

Authors
  1. Horst Olschewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Horst Olschewski .

Editor information

Editors and Affiliations

  1. Faculte´ de Me´decine, Univ Paris-Sud, Le Kremlin Bicêtre, France

    Marc Humbert

  2. Dep of Anasthesia and Critical Care, Harvard Medical School Massachusetts General Hospital, Boston, Massachusetts, USA

    Oleg V. Evgenov

  3. Cardiovascular Research, Bayer Pharma AG, Wuppertal, Germany

    Johannes-Peter Stasch

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Olschewski, H. (2013). Prostacyclins. In: Humbert, M., Evgenov, O., Stasch, JP. (eds) Pharmacotherapy of Pulmonary Hypertension. Handbook of Experimental Pharmacology, vol 218. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38664-0_8

Download citation

Publish with us

Policies and ethics

Search

Navigation